Program
relacorilant
Also written as “Relacorilant”, “CORT125134” and “Relacorilant 150 mg”.
Its studies are mostly in Cushing Syndrome · Ovarian Neoplasms · Carcinoma, Pancreatic Ductal · Adrenocortical Carcinoma · Pancreatic Neoplasms, led by Corcept Therapeutics.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Corcept Therapeutics | 223 open or running | phase 3since Sep 27, 2018 | Apr 11, 2016 | Dec 2026phase 2 · NCT03604198 |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
Before these, 5 studies since Apr 11, 2016.
- Mar 1, 2018Phase 1 study in HealthyNCT03457597 · 27 enrolled · United States
- Apr 3, 2018Phase 1 study in HealthyNCT03512548 · 52 enrolled · United States
- May 1, 2018Phase 2 study in Cushing SyndromeNCT03604198 · 125 enrolled · United States, Austria, Canada and more
- May 17, 2018Phase 1 study in HealthyNCT03540836 · 30 enrolled · United States
- Sep 27, 2018Phase 3 study in Cushing SyndromeNCT03697109 · 152 enrolled · United States, Austria, Bulgaria and more
- Dec 13, 2018Phase 2 study in Ovarian NeoplasmsNCT03776812 · 178 enrolled · United States, Belgium, Canada and more
- Feb 27, 2020Phase 3 study in Cushing SyndromeNCT04308590 · 137 enrolled · United States, Austria, Bulgaria and more
- Mar 13, 2020Phase 3 study in Pancreatic NeoplasmsNCT04329949 · 43 enrolled · United States
- Apr 30, 2020Phase 1 study in Adrenocortical CarcinomaNCT04373265 · 15 enrolled · United States
- Jan 29, 2021Phase 1 study in HealthyNCT04795479 · 36 enrolled · United States
- Feb 4, 2022Phase 3 study in Ovarian NeoplasmsNCT05257408 · 381 enrolled · United States, Argentina, Australia and more
- Apr 18, 2022Phase 1 study in Cushing SyndromeNCT05347979 · 30 enrolled · United States
- Oct 17, 20234 phase 1 studiesNCT06094790, NCT06094738, NCT06094725 and 1 more
- Nov 3, 2025Phase 2 study in AdenocarcinomaNCT07259317 · 80 planned · United States
Ahead
- Dec 2026Primary completion: phase 2 study in Cushing SyndromeNCT03604198
- Sep 2027Primary completion: phase 2 study in AdenocarcinomaNCT07259317
TargetBeta
“Glucocorticoid receptor antagonist”ChEMBL 37, by rule
Other programs on NR3C1
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| Dexamethasonerule | AbbVie | phase 4 | 174 |
| Budesoniderule | AstraZeneca | phase 4 | 167 |
| fluticasone furoaterule | GlaxoSmithKline | phase 4 | 97 |
| Prednisonerule | Johnson & Johnson | phase 4 | 65 |
| Beclomethasonerule | Chiesi Farmaceutici | phase 4 | 46 |
| Prednisolonerule | Sanofi | phase 4 | 34 |
| betamethasone dipropionaterule | LEO Pharma | phase 4 | 27 |
| Methylprednisolonerule | Pfizer | phase 4 | 23 |
| dexamethasone phosphaterule | eyegate-pharmaceuticals-inc | phase 4 | 21 |
| vamorolonerule | reveragen-biopharma-inc | phase 4 | 11 |
| Betamethasonerule | LEO Pharma | phase 4 | 9 |
| Triamcinolonerule | research-insight-llc | phase 4 | 5 |
Studies
All 22 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07259317Adenocarcinoma · United States | 2 | Recruiting | Sep 2027 | 80 |
| NCT06094790Healthy · United States | 1 | Completed | Nov 15, 2017 | 32 |
| NCT06094738Healthy · United States | 1 | Completed | Nov 16, 2020 | 30 |
| NCT06094725Hepatic Impairment · United States | 1 | Completed | Dec 14, 2020 | 30 |
| NCT06094712Healthy · United States | 1 | Completed | Apr 27, 2016 | 8 |
| NCT05347979Cushing Syndrome · United States | 1 | Completed | Jul 19, 2022 | 30 |
| NCT05257408Ovarian Neoplasms · United States, Argentina, Australia and more | 3 | Active, not recruiting | Mar 31, 2025 | 381 |
| NCT04795479Healthy · United States | 1 | Completed | May 17, 2021 | 36 |
| NCT04373265Adrenocortical Carcinoma · United States | 1 | Completed | Oct 17, 2023 | 15 |
| NCT04329949Pancreatic Neoplasms · United States | 3 | Terminated | Aug 23, 2021 | 43 |
| NCT04308590Cushing Syndrome · United States, Austria, Bulgaria and more | 3 | Completed | Sep 19, 2024 | 137 |
| NCT03776812Ovarian Neoplasms · United States, Belgium, Canada and more | 2 | Completed | Mar 16, 2021 | 178 |
| NCT03697109Cushing Syndrome · United States, Austria, Bulgaria and more | 3 | Completed | Apr 8, 2024 | 152 |
| NCT03540836Healthy · United States | 1 | Completed | Jul 16, 2018 | 30 |
| NCT03604198Cushing Syndrome · United States, Austria, Canada and more | 2 | Active, not recruiting | Dec 2026 | 125 |
| NCT03512548Healthy · United States | 1 | Completed | Jul 29, 2019 | 52 |
| NCT03457597Healthy · United States | 1 | Completed | Apr 15, 2018 | 27 |
| NCT03442621Healthy · United States | 1 | Completed | Feb 28, 2018 | 30 |
| NCT03508635Healthy · United Kingdom | 1 | Completed | Dec 2015 | 130 |
| NCT03067376Healthy · United Kingdom | 1 | Completed | Sep 2016 | 9 |
| NCT02804750Cushing Syndrome · United States, Hungary, Italy and more | 2 | Completed | Sep 2018 | 35 |
| NCT02762981Triple Negative Breast Neoplasms · United States | 2 | Completed | May 12, 2020 | 85 |
How it is read
Names in the registry
- “Relacorilant”, 9 entries
- “CORT125134”, 3 entries
- “relacorilant”, 1 entry
- “Relacorilant 150 mg”, 1 entry
- “Relacorilant, 100 mg and 25 mg”, 1 entry
Conditions, from the studies’ own filings
- Cushing Syndrome, 5 studies
- Ovarian Neoplasms, 2 studies
- Carcinoma, Pancreatic Ductal, 1 study
- Adrenocortical Carcinoma, 1 study
- Pancreatic Neoplasms, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.